Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham ESA Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedMass General Brigham Health PlanPolicy N/A

    Erythropoiesis-Stimulating Agents

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Aranesp, Epogen, Procrit, and Retacrit under the MassHealth UPPL medical benefit. Coverage is limited to specified anemia-related diagnoses and requires diagnosis-specific clinical criteria, documentation, and authorization durations.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyErythropoiesis-Stimulating Agents
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit current-treatment records for members whose coverage became effective within the prior 90 days.
    SourceLink
    POLICY UPDATE CHANGES

    Hemoglobin thresholds in continuation criteria were increased from 11 to 11.5 g/dL.

    A criterion was added requiring the requested strength to be the minimum strength necessary to administer the requested dose for all indications.

    Epogen was designated as the preferred epoetin alfa product, with prior-use criteria previously applied to Procrit and Retacrit.

    Mircera was removed from the policy because it was available under the medical benefit without prior authorization.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4ESA products addressed
    7Approved diagnosis categories
    90 daysNew-plan documentation window
    MedicalApplicable benefit
    11.5 g/dLContinuation threshold
    12 monthsMaximum selected duration

    Coverage Criteria

    General Authorization Pathway

    Coverage may be authorized through either the new-plan current-treatment pathway or when all applicable clinical criteria for the requested indication are met.

    ONE of the following

    • Member is new to the plan, as evidenced by a coverage effective date of less than or equal to 90 days, and medical records document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.
    • All applicable clinical criteria for the requested indication are met.

    Initial Therapy — Chronic Kidney Disease Anemia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of anemia due to chronic kidney disease.
    • ONE of the following

      • Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
      • Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
      • Member is stable on one of the ESA agents previously and Hb is ≤ 11.5 g/dL.≤ 11.5 g/dL; dated within the last 60 days
      • Member is stable on one of the ESA agents previously and Hb is > 11.5 g/dL, with prescriber attestation that the erythropoietin dose will be held or reduced to remain within the appropriate target.> 11.5 g/dL; dated within the last 60 days
    • Estimated or measured glomerular filtration rate (GFR) is ≤ 60 mL/min.≤ 60 mL/min

      For all GFR calculations, use the calculator provided by the National Kidney Foundation.

    • Member is not receiving hemodialysis.

      If the member is receiving hemodialysis, the prescriber must contact the dialysis clinic for the proper billing procedure because the medication is provided by the clinic.

    • Requested strength is the minimum strength necessary to administer the requested dose.

    Initial Therapy — Post-Renal Transplant Anemia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of anemia due to renal transplant.
    • ONE of the following

      • Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
      • Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
    • Member is not receiving hemodialysis.

      If the member is receiving hemodialysis, the prescriber must contact the dialysis clinic for the proper billing procedure because the medication is provided by the clinic.

    Initial Therapy — Cancer Chemotherapy Anemia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of anemia due to chemotherapy treatment for cancer.
    • ONE of the following

      • Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
      • Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
    • Requested strength is the minimum strength necessary to administer the requested dose.

    Initial Therapy — HIV Regimen Anemia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of anemia due to a myelosuppressive medication regimen for HIV.
    • ONE of the following

      • Requested agent will be used in combination with zidovudine or a zidovudine-containing product.
      • All other causes of anemia have been ruled out, including iron deficiency, vitamin B12 deficiency, folate deficiency, and hemolysis.
    • ONE of the following

      • Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days

    Initial Therapy — Hepatitis C Regimen Anemia

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of anemia due to a myelosuppressive medication regimen for hepatitis C.
    • ONE of the following

      • Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
      • Hb is < 10 g/dL and the member is currently being treated with a hepatitis C regimen containing an interferon product, with or without ribavirin.< 10 g/dL; dated within the last 60 days
      • Hb is < 10 g/dL, the member is currently being treated with a hepatitis C regimen containing ribavirin without interferon, and ribavirin dose reduction to 600 mg per day has been attempted.< 10 g/dL; dated within the last 60 days

    Initial Therapy — Surgery

    Covered when ALL of the following are met:

    ALL of the following

    • Indication is to decrease the need for blood transfusion with surgery, including for members who refuse blood donation because of religious beliefs.
    • Hb is ≤ 13 g/dL.≤ 13 g/dL; dated within the last 30 days
    • Surgery is planned within the next 3 months.

      Document the anticipated date of surgery.

    • Requested strength is the minimum strength necessary to administer the requested dose.

    Initial Therapy — Idiopathic Sideroblastic Anemia or MDS

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following diagnoses

      • Idiopathic sideroblastic anemia.
      • Anemia due to myelodysplastic syndrome (MDS).
    • ONE of the following

      • Hemoglobin (Hb) is < 10 g/dL.< 10 g/dL; dated within the last 60 days
      • Member is a child and is symptomatic with an Hb ≤ 11 g/dL.

    Continuation Therapy — CKD or Post-Renal Transplant

    Covered when ANY of the following are met:

    ANY of the following

    • Hb level is < 11.5 g/dL.< 11.5 g/dL; dated within the last 60 days
    • Hb level is ≥ 11.5 g/dL and the request addresses that the erythropoietin dose will be held or reduced to remain within the appropriate target.≥ 11.5 g/dL; dated within the last 60 days

    Continuation Therapy — Sideroblastic Anemia or MDS

    Covered when ANY of the following are met:

    ANY of the following

    • Hb level is ≤ 12 g/dL.≤ 12 g/dL; dated within the last 60 days
    • Hb level is > 12 g/dL and the request addresses that the erythropoietin dose will be held or reduced to remain within the appropriate target.> 12 g/dL; dated within the last 60 days

    Continuation Therapy — Cancer Chemotherapy or HIV

    Covered when ALL of the following are met:

    ALL of the following

    • Hb level is ≤ 12 g/dL.≤ 12 g/dL; dated within the last 60 days
    • Requested agent will be used in combination with the causative agent.

    Continuation Therapy — Hepatitis C

    Covered when the following criterion is met:

    Documentation that the member will continue to receive the causative agent.

    Coverage under this policy is for the medical benefit. Aranesp, Epogen, and Procrit are also available under the pharmacy benefit; refer to the MassHealth Drug List for pharmacy-benefit coverage and criteria.

    Clinical Thresholds and Requirements

    Chronic kidney disease hemoglobin
    Adult Hb thresholdHb < 10 g/dL, dated within the last 60 days
    Symptomatic child thresholdChild is symptomatic with Hb ≤ 11 g/dL
    Stable prior ESA useStable on a prior ESA with Hb ≤ 11.5 g/dL, dated within the last 60 days; or Hb > 11.5 g/dL with prescriber attestation that the erythropoietin dose will be held or reduced to remain within the appropriate target
    Chronic kidney disease GFR
    GFR typeEstimated or measured glomerular filtration rate
    CKD thresholdGFR ≤ 60 mL/min
    Calculation guidance

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa) under the MassHealth UPPL medical benefit. These products may also be available under the pharmacy benefit; consult the MassHealth Drug List for pharmacy coverage and criteria.

    • Submit requests through the medical benefit authorization process.
    • Medical benefit contact: 833-895-2611; fax: 888-656-6671.
    • Pharmacy benefit contact: 800-711-4555; fax: 844-403-1029.
    Documentation Required

    New-Plan Member Pathway

    For a member whose coverage effective date is less than or equal to 90 days, submit medical records showing that the member is currently receiving treatment with the requested drug. This pathway does not apply when the product was obtained as samples or through a manufacturer patient assistance program.

    Policy Background

    Erythropoiesis-stimulating agents (ESAs) promote the growth and differentiation of stem cells into colonies of specific blood cells. This policy addresses ESA use for anemia associated with chronic kidney disease, renal transplantation, cancer chemotherapy, myelosuppressive HIV or hepatitis C regimens, surgery-related reduction in the need for blood transfusion, and idiopathic sideroblastic anemia or myelodysplastic syndrome.

    Definitions

    Erythropoiesis-stimulating agents (ESAs)
    DefinitionAgents that promote the growth and differentiation of stem cells into colonies of specific blood cells
    Products addressedAranesp, Epogen, Procrit, and Retacrit
    Clinical roleErythropoiesis-stimulating agents are used in the policy for specified anemia-related indications
    GFR
    Full termGlomerular filtration rate
    MeasurementGFR may be estimated or measured
    CKD policy thresholdThe chronic kidney disease indication requires GFR ≤ 60 mL/min

    Initial Therapy Criteria

    Chronic kidney disease — initial therapy

    Initial therapy for anemia due to chronic kidney disease requires all of the following.

    CKD anemia criteria

    • Diagnosis of anemia due to chronic kidney disease; estimated or measured GFR is ≤ 60 mL/min; member is not receiving hemodialysis; and the requested strength is the minimum strength necessary for the requested dose.GFR ≤ 60 mL/min

      Use the National Kidney Foundation calculator for GFR calculations.

    • Hemoglobin or prior-ESA stability requirement

      • Hb is less than 10 g/dL, dated within the last 60 days.
      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.

    Continuation Therapy Criteria

    CKD or post-renal transplant — continuation therapy

    Continuation therapy for CKD or post-renal transplant anemia requires one of the following.

    Hemoglobin or dose management

    • Hb is less than 11.5 g/dL, dated within the last 60 days.
    • Hb is ≥ 11.5 g/dL, dated within the last 60 days, and the request addresses whether the erythropoietin dose will be held or reduced to remain within the appropriate target.

    Idiopathic sideroblastic anemia or MDS — continuation therapy

    Continuation therapy for idiopathic sideroblastic anemia or MDS requires one of the following.

    Hemoglobin or dose management

    • Hb is ≤ 12 g/dL, dated within the last 60 days.

    Site of Care and Benefit

    Billing Rule

    Confirm the benefit and site of care

    This policy applies under the medical benefit. Aranesp, Epogen, and Procrit are also available under the pharmacy benefit; consult the MassHealth Drug List for pharmacy-benefit coverage and criteria.

    • Use the medical-benefit contact information for medical-benefit authorization and billing.
    • The pharmacy-benefit pathway has separate coverage criteria.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyErythropoiesis-Stimulating Agents
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit current-treatment records for members whose coverage became effective within the prior 90 days.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and RequirementsProvider Actions and Submission RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaSite of Care and Benefit
    Requested strength is the minimum strength necessary to administer the requested dose.
  1. Member is a child and is symptomatic with an Hb ≤ 11 g/dL.
  2. Requested strength is the minimum strength necessary to administer the requested dose.
    • ONE of the following

      • Hb is < 8.5 g/dL.< 8.5 g/dL; dated within the last 60 days
      • Hb is < 12 g/dL and the member has a history of cardiac disease.< 12 g/dL; dated within the last 60 days
  3. Requested strength is the minimum strength necessary to administer the requested dose.
  4. Requested strength is the minimum strength necessary to administer the requested dose.
    Use the calculator provided by the National Kidney Foundation for all GFR calculations
    General anemia hemoglobin
    Standard Hb thresholdHb < 10 g/dL, dated within the last 60 days
    Symptomatic child thresholdChild is symptomatic with Hb ≤ 11 g/dL
    Applicable indicationsPost-renal transplant, cancer chemotherapy, myelosuppressive HIV regimen, hepatitis C regimen, and idiopathic sideroblastic anemia or MDS
    Hepatitis C anemia thresholds
    Interferon-containing regimenHb < 10 g/dL, dated within the last 60 days, while receiving a hepatitis C regimen containing interferon, with or without ribavirin
    Ribavirin-only regimenHb < 10 g/dL, dated within the last 60 days, after attempted ribavirin dose reduction to 600 mg per day
    Ribavirin reduction not indicatedRibavirin without interferon when dose reduction to 600 mg per day is not indicated because Hb < 8.5 g/dL, or Hb < 12 g/dL with a history of cardiac disease
    Surgery hemoglobin
    Hemoglobin thresholdHb ≤ 13 g/dL
    Laboratory timingHemoglobin must be dated within the last 30 days
    Surgery timingSurgery planned within the next 3 months
    Continuation hemoglobin: CKD or post-renal transplant
    Hemoglobin thresholdHb < 11.5 g/dL, dated within the last 60 days
    Higher Hb optionHb ≥ 11.5 g/dL, dated within the last 60 days, when the request addresses whether the erythropoietin dose will be held or reduced
    Applicable conditionsChronic kidney disease or post-renal transplant anemia
    Continuation hemoglobin: sideroblastic anemia or MDS
    Hemoglobin thresholdHb ≤ 12 g/dL, dated within the last 60 days
    Higher Hb optionHb > 12 g/dL, dated within the last 60 days, when the request addresses whether the erythropoietin dose will be held or reduced
    Applicable conditionsIdiopathic sideroblastic anemia or myelodysplastic syndrome
    Continuation hemoglobin: cancer chemotherapy or HIV regimen
    Hemoglobin thresholdHb ≤ 12 g/dL, dated within the last 60 days
    Causative treatmentThe requested agent will be used in combination with the causative agent
    Applicable indicationsCancer chemotherapy or a myelosuppressive medication regimen for HIV
    Hemoglobin continuation threshold
    Revised continuation threshold11.5 g/dL
    Threshold changeContinuation hemoglobin thresholds were increased from 11 to 11.5 g/dL
    Higher Hb requestsWhen Hb is at or above 11.5 g/dL for CKD or post-renal transplant anemia, the request must address holding or reducing the erythropoietin dose to remain within the appropriate target
    • Document the member's coverage effective date.
    • Include current-treatment documentation for the requested drug.
    • Do not rely on samples or manufacturer patient assistance programs as evidence of current treatment.
    Documentation Required

    Document Current ESA Treatment

    Submit current treatment records for new-plan members that demonstrate ongoing therapy with the requested ESA, including the drug and relevant treatment details needed to establish current use.

    • Records must show current treatment with the requested drug.
    • Records obtained solely from samples or a manufacturer's patient assistance program do not satisfy this requirement.
    Documentation Required

    Indication-Specific Clinical Documentation

    Submit indication-specific clinical documentation establishing the diagnosis and all supporting clinical information for the applicable approved indication.

    • Chronic kidney disease: document anemia due to CKD; hemoglobin (Hb) within the applicable threshold and date; estimated or measured GFR; and, when applicable, pediatric symptoms, prior ESA stability, or the plan to hold or reduce erythropoietin. Use the National Kidney Foundation calculator for GFR calculations.
    • Post-renal transplant: document anemia due to renal transplant, Hb within the applicable threshold and date, and whether the member is receiving hemodialysis.
    • Cancer chemotherapy: document anemia due to chemotherapy treatment for cancer, Hb within the applicable threshold and date, and that the requested agent will be used with the causative agent when applicable.
    • HIV: document anemia due to a myelosuppressive HIV medication regimen; use with zidovudine or a zidovudine-containing product, or documentation that iron, vitamin B12, folate deficiency, and hemolysis have been ruled out; include Hb and date.
    • Hepatitis C: document anemia due to the myelosuppressive hepatitis C regimen, the current interferon and/or ribavirin regimen, Hb and date, any ribavirin reduction to 600 mg per day that was attempted, or why reduction is not indicated, including qualifying Hb or cardiac disease documentation.
    • Surgery: document the transfusion-reduction indication, including religious refusal of blood donation when applicable, Hb within the last 30 days, and the planned surgery date within the next 3 months.
    • Idiopathic sideroblastic anemia/MDS: document idiopathic sideroblastic anemia or anemia due to MDS, Hb within the applicable threshold and date, and any required plan to hold or reduce erythropoietin.
    • For applicable requests, include documentation that the member will continue receiving the causative agent.
    Documentation Required

    Renal Function and Dialysis Documentation

    For CKD-related or post-renal-transplant anemia requests, provide the required renal-function and dialysis documentation. Hemodialysis affects the billing pathway because the dialysis clinic provides the medication.

    • For CKD, submit estimated or measured GFR of ≤ 60 mL/min and identify the calculation method; use the National Kidney Foundation calculator.
    • Document that the member is not receiving hemodialysis when required by the applicable indication.
    • If the member receives hemodialysis, the prescriber must contact the dialysis clinic for the proper billing procedure.
    Documentation Required

    Surgical Transfusion-Reduction Documentation

    For requests to reduce the need for transfusion in surgery patients, document the planned surgery and recent hemoglobin result.

    • Provide the anticipated surgery date, which must be within the next 3 months.
    • Provide Hb ≤ 13 g/dL dated within the last 30 days.
    • Document the transfusion-reduction indication, including refusal of blood donation due to religious beliefs when applicable.
    Denial Risk

    Unapproved Diagnosis

    Requests for diagnoses outside the plan's approved anemia indications do not meet the indication requirements for coverage.

    • Approved indications include anemia due to CKD; anemia in post-renal-transplant patients; anemia in cancer chemotherapy-treated patients; anemia due to myelosuppressive regimens for HIV or hepatitis C; reduction of transfusion need in surgery patients; and anemia due to idiopathic sideroblastic anemia/MDS.
    • Clearly link the anemia to the applicable approved disease, treatment regimen, or surgical indication.
    Denial Risk

    Indication-Specific Criteria Not Met

    Requests may be denied when indication-specific requirements are not documented, including required Hb thresholds and dates, qualifying treatment combinations, exclusion of other causes, required dose-reduction attempts, renal or dialysis requirements, or surgical timing.

    • Provide Hb results within 60 days when required; surgical requests require Hb dated within 30 days.
    • For CKD, document GFR ≤ 60 mL/min and no hemodialysis; for hemodialysis, follow the dialysis-clinic billing process.
    • For HIV, document zidovudine use or that iron, vitamin B12, folate deficiency, and hemolysis have been ruled out.
    • For hepatitis C, document the qualifying interferon/ribavirin regimen, required ribavirin reduction attempt or reason it is not indicated, and continuation of the causative agent.
    • For chemotherapy and HIV-related anemia, document use of the requested agent with the causative agent when required.
    • For surgery, document the planned procedure and anticipated date within 3 months.
    • For CKD, post-transplant, sideroblastic anemia/MDS, chemotherapy, HIV, and hepatitis C criteria, include any required pediatric symptoms, prior ESA stability, dose-hold or dose-reduction plan, or causative-agent continuation documentation.
    Denial Risk

    Requested Strength Must Be Minimal

    The requested strength must be the minimum strength necessary to administer the requested dose. Requests for a higher-than-necessary strength may be denied.

    • Document the prescribed dose and why the requested product strength is the minimum strength needed to administer it.
    • Apply this requirement to CKD, post-renal-transplant, chemotherapy, HIV, hepatitis C, surgical transfusion-reduction, and idiopathic sideroblastic anemia/MDS requests.
    Member is stable on a prior ESA and has Hb ≤ 11.5 g/dL, dated within the last 60 days.
  5. Member is stable on a prior ESA and has Hb > 11.5 g/dL, dated within the last 60 days, and the prescriber attests that the erythropoietin dose will be held or reduced to remain within the appropriate target.
  6. Post-renal transplant — initial therapy

    Initial therapy for anemia due to renal transplant requires all of the following.

    Post-renal transplant anemia criteria

    • Diagnosis of anemia due to renal transplant; member is not receiving hemodialysis; and the requested strength is the minimum strength necessary for the requested dose.
    • Hemoglobin requirement

      • Hb is less than 10 g/dL, dated within the last 60 days.
      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.

    Cancer chemotherapy — initial therapy

    Initial therapy for anemia due to chemotherapy treatment for cancer requires all of the following.

    Cancer chemotherapy anemia criteria

    • Diagnosis of anemia due to chemotherapy treatment for cancer and the requested strength is the minimum strength necessary for the requested dose.
    • Hemoglobin requirement

      • Hb is less than 10 g/dL, dated within the last 60 days.
      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.

    HIV regimen — initial therapy

    Initial therapy for anemia due to a myelosuppressive HIV medication regimen requires all of the following.

    HIV anemia criteria

    • Diagnosis of anemia due to a myelosuppressive medication regimen for HIV and the requested strength is the minimum strength necessary for the requested dose.
    • Medication-causation requirement

      • Requested agent will be used in combination with zidovudine or a zidovudine-containing product.
      • All other causes of anemia have been ruled out, including iron deficiency, vitamin B12 deficiency, folate deficiency, and hemolysis.
    • Hemoglobin requirement

      • Hb is less than 10 g/dL, dated within the last 60 days.
      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.

    Hepatitis C regimen — initial therapy

    Initial therapy for anemia due to a myelosuppressive hepatitis C medication regimen requires all of the following.

    Hepatitis C anemia criteria

    • Diagnosis of anemia due to a myelosuppressive medication regimen for hepatitis C and the requested strength is the minimum strength necessary for the requested dose.
    • Qualifying clinical and treatment condition

      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.
      • Hb is less than 10 g/dL, dated within the last 60 days, while receiving an interferon-containing hepatitis C regimen with or without ribavirin.
      • Hb is less than 10 g/dL, dated within the last 60 days, while receiving ribavirin without interferon after attempted ribavirin dose reduction to 600 mg per day.
      • Member is receiving ribavirin without interferon and dose reduction to 600 mg per day is not indicated because Hb is less than 8.5 g/dL, or Hb is less than 12 g/dL with a history of cardiac disease, with the applicable Hb dated within the last 60 days.

    Surgery — initial therapy

    Initial therapy to decrease the need for blood transfusion in surgery patients requires all of the following.

    Surgery criteria: There is an indication to decrease the need for blood transfusion with surgery, including for members who refuse blood donation because of religious beliefs; Hb is ≤ 13 g/dL, dated within the last 30 days; surgery is planned within the next 3 months; and the requested strength is the minimum strength necessary to administer the requested dose.Hb ≤ 13 g/dL; surgery within 3 months

    Idiopathic sideroblastic anemia or MDS — initial therapy

    Initial therapy for anemia due to idiopathic sideroblastic anemia or MDS requires all of the following.

    Sideroblastic anemia or MDS criteria

    • Diagnosis of idiopathic sideroblastic anemia or anemia due to myelodysplastic syndrome, and the requested strength is the minimum strength necessary for the requested dose.
    • Hemoglobin requirement

      • Hb is less than 10 g/dL, dated within the last 60 days.
      • Member is a child, is symptomatic, and has Hb ≤ 11 g/dL.
  7. Hb is > 12 g/dL, dated within the last 60 days, and the request addresses whether the erythropoietin dose will be held or reduced to remain within the appropriate target.
  8. Cancer chemotherapy or HIV — continuation therapy

    Continuation therapy during cancer chemotherapy or a myelosuppressive HIV regimen requires all of the following.

    Ongoing causative treatment: Hb is ≤ 12 g/dL, dated within the last 60 days, and the requested agent will be used in combination with the causative agent.Hb ≤ 12 g/dL

    Hepatitis C — continuation therapy

    Continuation therapy during a myelosuppressive hepatitis C regimen requires the following.

    Ongoing causative treatment: Documentation shows that the member will continue to receive the causative agent.

    Applies with or without ribavirin dose reduction.